Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma
Status:
Withdrawn
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The phase I trial aims to determine the recommended phase II dose (RP2D) of vandetanib in
combination with standard radiation therapy, 131I-mIBG, in patients with advanced
phaeochromocytoma (phaeo) and paraganglioma (PG) by assessing the safety and tolerability of
the combination treatment.